Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.51 |
| ▸ | DHODH | Q02127 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025593 | 0.82 | MAPT (0.43) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL641899 | 0.81 | PDE10A (0.66) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29377848 | 0.81 | PDE10A (0.66) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| SCHEMBL8080052 | 0.79 | ALDH1A1 (0.64) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| SCHEMBL13313361 | 0.79 | CYP1A2 (0.60) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| Iodide SCHEMBL8029601 | 0.79 | PDE10A (0.63) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1603404 | 0.79 | PDE10A (0.63) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| Iodide SCHEMBL8029606 | 0.79 | PDE10A (0.63) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9597551 | 0.79 | PDE10A (0.63) | KMT2AMEN1CYP2C19KDM4EALDH1A1 | |
| Water SCHEMBL2991911 | 0.79 | PDE10A (0.63) | KMT2AMEN1CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635437-B2 | Useful in methods for producing light and in assays for phosphatase enzymes and enzyme inhibitors and in assays employing enzyme-labeled specific binding pairs | LUMIGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-0819119-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR GENERATING CHEMILUMINESCENCE WITH PHOSPHATASE ENZYMES | LUMIGEN INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030023089-A1 | Compounds, compositions and methods for generating chemiluminescence with phosphatase enzymes | AKHAVAN-TAFTI HASHEM (US) | 2003-01-30 | — | — | US | disclosed |
| US-6296787-B1 | ACRIDINE AND PHENANTHRIDINE ALKENYL PHOSPHATE DERIVATIVES | LUMIGEN, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6270695-B1 | HETEROCYCLIC COMPOUNDS WITH EXOCYCLIC DOUBLE BOND HAVING PHOSPHATE GROUP ATTACHED TO DISTAL CARBON; DETECTION SENSITIVITY | LUMIGEN, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6218137-B1 | SENSITIVE QUANTITATIVE ANALYSIS USING COMPOUND HAVING A HETEROCYCLIC RING SYSTEM BEARING AN EXOCYCLIC CARBON-CARBON DOUBLE BOND WHICH IS SUBSTITUTED AT DISTAL CARBON WITH PHOSPHATE GROUP AND OXYGEN OR SULFUR GROUP | LUMIGEN, INC. | 2001-04-17 | — | — | US | disclosed |
| US-6139782-A | A CHEMILUMINESCENT CONTAINING A HETEROCYCLIC RING GROUP AND AN ENOL PHOSPHATE GROUP WHICH REACT WITH OXYGEN UPON REMOVAL OF PHOSPHATE GROUP WITH A PHOSPHATASE ENZYME TO PRODUCE AN ENOLATE WHICH REACTS WITH TO PRODUCE CHEMILUMINOESCENCE | LUMIGEN, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6110910-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTIRHEUMATIC AGENTS, ANTICARCINOGENIC AGENTS | DUPONT PHARMACEUTICALS (US) | 2000-08-29 | — | — | US | disclosed |
| US-6090571-A | REACTING PHOSPHATASE WITH NITROGEN-CONTAINING HETEROCYCLIC RING SYSTEM HAVING AN ENOL PHOSPHATE GROUP, DETECTING THE CHEMILUMINESCENCE, AND RELATING TO AMOUNT OF ANALYTE | LUMIGEN, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6045727-A | NITROGEN CONTAINING HETEROCYCLIC RING SYSTEM BEARING AN EXOCYCLIC CARBON-CARBON DOUBLE BOND. THE DOUBLE BOND IS FURTHER SUBSTITUTED AT THE DISTAL CARBON WITH A PHOSPHATE GROUP AND AN OXYGEN OR SULFUR ATOM-CONTAINING GROUP. | LUMIGEN, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5639759-A | ORGAN TRANSPLANTATION; AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023089-A1 | Compounds, compositions and methods for generating chemiluminescence with phosphatase enzymes | PPP6C, PPP4C, PPP2CA | KMT2A 4778/4885MEN1 4650/4885CYP2C19 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.